Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2016-04-28
Target enrollment:
Participant gender:
Summary
This is an 8-week, single centre, randomized, parallel-group, double-blind,
placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific
insulin sensitivity in patients with Type 2 diabetes mellitus
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Collaborators:
43183 Mölndal Antaros Medical Antaros Medical AB Bioventure Hub Sweden